Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops a pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis to address diseases driven by pathological tissue scarring. Its lead compound is VB0004, currently under phase Ib clinical human trial, which targets the prevention and reversal of fibrosis in the lungs, heart, and kidneys. The company was incorporated in 2005 and is based in Rosebery, Australia.
Research context
Vectus Biosystems Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Vectus Biosystems Limited is currently in a long term uptrend where the price is trading 14.2% above its 200 day moving average.
From a valuation standpoint, the stock is 538.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1644.5.
Vectus Biosystems Limited's total revenue rose by 22759.1% to $50K since the same quarter in the previous year.
Its net income has dropped by 104.9% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 31.3% to $-692K since the same quarter in the previous year.
Based on the above factors, Vectus Biosystems Limited gets an overall score of 3/5.